Navigation Links
New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association
Date:3/2/2010

NASHVILLE, Tenn., March 2 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that data from a recent study evaluating the safety and efficacy of Caldolor® (ibuprofen) Injection in treating pain and fever in hospitalized burn patients will be presented at the 42nd Annual Meeting of the American Burn Association in Boston.

The new data will be displayed in a poster presentation on Wednesday, March 10, from 12:15 p.m. to 1:15 p.m. ET. The study, entitled "A Multi-Center, Randomized, Double-Blind Trial of Ibuprofen Injection for the Treatment of Fever and Pain in the Burn Patient," will be presented by Dr. John T. Promes, Associate Director for Surgical Education at Orlando Regional Medical Center, Assistant Professor of Surgery at the University of Central Florida College of Medicine, and Clinical Assistant Professor in the Department of Surgery at the Florida State University College of Medicine.

Concurrent with the presentation on March 10th, the poster will be available on Cumberland Pharmaceuticals' website at http://investor.shareholder.com/cpix/events.cfm. Copies may also be obtained by contacting the Company at 615-255-0068.

The American Burn Association has more than 3,500 members in the United States, Canada, Europe, Asia, and Latin America. Members include physicians, nurses, occupational and physical therapists, researchers, social workers, firefighters, and hospitals with burn centers who are dedicated to promoting and supporting burn-related research, education, care, rehabilitation, and prevention. For more information, please visit www.ameriburn.org.

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, including boxed warning, visit www.caldolor.com.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning and Kristalose® (lactulose) for Oral Solution, a prescription laxative. The Company also recently launched Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company completed the initial public offering of its common stock in August 2009. For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.

SOURCE Cumberland Pharmaceuticals Inc.

Back to top

RELATED LINKS
http://www.cumberlandpharma.com

'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Cumberland Pharmaceuticals Launches Caldolor(R) in the United States for Treatment of Pain and Fever
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New study shows promise in reducing surgical risks associated with surgical bleeding
4. Study, meta-analysis examine factors associated with death from heatstroke
5. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
6. Study says COPD testing is not measuring up
7. Preclinical study suggests organ-transplant drug may aid in lupus fight
8. Ability to cope with stress can increase good cholesterol in older white men, study finds
9. High alcohol consumption increases stroke risk, Tulane study says
10. Mailman School of Public Health study examines link between racial discrimination and substance use
11. Pitt study finds inequality in tobacco advertising
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... 2016 , ... DDi , a Makro company, makes ... its expertise in eClinical Solutions. DDi has built its solution competency with a ... global clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of ... Evangeline Parishes. The purpose of these scholarships is to encourage applicants to pursue ... to seek employment within these two parishes. , “We have available jobs in ...
(Date:2/12/2016)... Falls Church, VA (PRWEB) , ... February 12, 2016 , ... CDRH Enforcement Trends: , ... http://www.fdanews.com/cdrhenforcementtrends , As Winston Churchill said, “Those who don’t learn ... 2015 will show what to expect when they come knocking this year. But that takes ...
(Date:2/12/2016)... Angeles, CA (PRWEB) , ... February 12, 2016 , ... ... With a hectic schedule, a demanding job, and no time to decompress, Rabinowitz found ... she dedicated herself to meditation for its impact on her life, implementing a 20-minute-per-day ...
(Date:2/12/2016)... ... February 12, 2016 , ... The ... Zuckerberg San Francisco General Hospital on April 5-7. The series is a multi-day, ... new habits. The workshops cover a broad range of topics, including coaching skills, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  Sequent Medical, Inc. announced today that ... evaluate the safety and effectiveness of the WEB™ Aneurysm ... intracranial aneurysms.  Prof Laurent Spelle , MD, Head ... Paris, France and Principal Investigator of the ... France and Germany.  Although patients with ruptured ...
(Date:2/12/2016)... 2016  OMS Supply, a large provider of oral ... today the recent launching of their new company website. ... features that enhance the user experience and enable practitioners ... --> --> Despite the ... that started in early 2016, they have already made ...
(Date:2/11/2016)... Feb. 11, 2016 - ... in Personalized Medicine and Cancer Therapy. - European ... Diagnostic Testing Markets. - Key Diagnostic Testing Markets. ... Molecular Diagnostics in Genetic Testing. - Molecular Diagnostics ... - Over-the-Counter Diagnostic Products World Markets. - ...
Breaking Medicine Technology: